

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

NCT05380414

Status	RECRUITING
Phase	Not Applicable
Sponsor	Centre Leon Berard
Enrollment	750 participants

Plain Language Summary

This study is collecting detailed genetic and molecular information from patients with advanced or metastatic pancreatic cancer to better understand what drives tumor growth and to identify potential new treatment targets.

****You may be eligible if...****

- You are over 18 with confirmed advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
- You have received no more than one prior chemotherapy treatment for metastatic disease
- Tumor tissue (from surgery or biopsy) is available for testing
- You have a life expectancy of more than 3 months
- You are in good overall health (performance status 0 or 1)

****You may NOT be eligible if...****

- A curative treatment option is still available to you
- You cannot safely provide blood samples
- You have another active cancer that is growing or being treated

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (6)

- Male or female patient > 18 years
 - metastatic or advanced PDAC
 - Patient pretreated with no more than one prior systemic chemotherapy for metastatic/advanced disease (radiotherapy is not counted as a line of therapy).
 - Availability of an archival representative FFPE tumor sample from primary tumor (surgery or diagnostic biopsy) and/or from metastatic lesion if metastatic disease at initial diagnosis with associated pathology report from an archival tumor block.
 - Life expectancy > 3 months
- ... and 1 more (see full listing online)

Exclusion (4)

- Curative therapy available
- Any condition contraindicated with blood sampling procedures required by the protocol.
- Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.

Locations (1 total)

<https://clinicaltrials.gov/study/NCT05380414>

Centre Léon Bérard, Lyon, France

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).